Conference Coverage

The Buck Stops Here: Rational Oversight for Hematologic Testing

Abstract 24: 2016 AVAHO Meeting


 

Complex hematological tests aid in establishing hematologic diagnoses, but can be quite costly. We hypothesized that certain diagnostic tests (specifically JAK2 at $175/test, BCR-ABL at $163/test, and flow cytometry at $275/test) that were being ordered without input from a hematologist were generally not indicated and expensive. We reviewed all of these tests sent between September 2013 and September 2015. 20/55 or 36% of JAK2 mutations, 19/37 or 51% of BCR-ABL mutations, and 47/74 or 63% of flow cytometry were completed without hematology input, primarily via primary care (72/86 or 84%). Tests that were ordered or recommended by hematology were excluded from the subsequent cost analysis. In total $19,500 was spent (without hematology input). One hematologist then reviewed the charts on every test that had been ordered not by hematology to determine if the test was clinically appropriate. 12/20 or 60% of JAK2 mutations, 19/19 or 100% of BCR mutations, and 44/47 or 94% of flow cytometry evaluations were felt to be unnecessary. Thus $17,300 of the $19,500 could have been saved had there been hematology input at the outset. This would have amounted to 86 e-consults over 2 years, which would be 1.2 extra consults/week; these consults generally take under 10 minutes, so less than 2 minutes/day. This all translates to ~$1,075 over 2 years of a hematologist’s salary, clearly more cost-effective than permitting everyone to be able to order these tests. We should consider recommending hematology input prior to allowing these tests (and perhaps other costly unusual hematology investigations) to be sent out, perhaps via a pop-up suggestion for a hematology e-consult when ordered; the e-consult would also be a tool to educate other providers on the appropriate use of these tests and may ultimately lead to a decrease in the ordering of these e-consults.

Recommended Reading

An Unusual Cause of Shortness of Breath: Primary Tracheal Basal Cell Adenocarcinoma
AVAHO
Can Serum Free Light Chains Be Used for the Early Diagnosis of Monoclonal Immunoglobulin-Secreting B-Cell and Plasma-Cell Diseases? (FULL)
AVAHO
Open Clinical Trials for Patients With Prostate Cancer
AVAHO
Faster Triage of Veterans With Head and Neck Cancer
AVAHO
Metastatic Small Cell Carcinoma of the Lung: An Unusual Cause of Acute Fulminant Hepatic Failure
AVAHO
Melanoma Registry Underreporting in the Veterans Health Administration
AVAHO
BRAF Inhibitor Resistance Reprograms Metabolic and Survival Pathways to Sensitize Melanoma Cells to Arginine Deprivation
AVAHO
Less Than 50% VAH Patients Receive Treatment for Stage IV Pancreatic Cancer: Care Comparison at VAH versus ACOS Certified Hospitals
AVAHO
Breast Cancer Risk Assessment and Utilization of Prevention Options Among Female Veterans: A Feasibility Pilot Study
AVAHO
Effect of Improved Screening in VAH on Melanoma
AVAHO